BeOne Medicines’ Tevimbra Combination Extends Median Survival to 27 Months in Gastroesophageal Cancer Trial
Bitget2026/10/23 14:15- BeOne Medicines reported sustained survival benefits for Tevimbra with Ziihera and chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma.
- Patients lived longer than with trastuzumab-based chemotherapy; the benefit over Ziihera with chemotherapy alone did not reach statistical significance.
- No new safety signals emerged in the Phase 3 HERIZON-GEA-01 trial.
- The results will be presented today at the European Society for Medical Oncology Congress 2026 in Madrid.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MINIMAX drops 10.8% in 1 hour
The battle for customer loyalty heats up ahead of the holiday season! Walmart (WMT.US) launches a $120 membership package, going head-to-head with Amazon Prime and Costco.
Walmart launched a joint membership package for Walmart+ and Sam’s Club Plus this week, directly competing with Amazon Prime and Costco.
Data: ETH falls below 2,300 USD
Survival period doubled! AstraZeneca's new stomach cancer drug Sone-ve aims for $5 billion in annual sales, ADC takes another step towards replacing chemotherapy
AstraZeneca's gastric cancer ADC doubles patient survival, extending life by five more months, aiming for annual sales of $5 billion; the company is racing with Takeda and Astellas to target Claudin 18.2.
Crypto prices
More
